Background: To obtain descriptive data on Singaporean thyroid cancer patients treated with radioiodine and to assess gender, race, and age at diagnosis as risk factors for metastasis or recurrence. Methods: This is a retrospective study of all thyroid cancer patients treated with radioiodine of any prescribed activity at our institution. Data collected included: age at diagnosis, gender, race, histopathological type, duration of follow-up, and metastasis at diagnosis (locoregional or distant) or recurrence at any time. Gender, race, and age at diagnosis were analyzed for possible associations with metastasis or recurrence. Results: A total of 1,657 thyroid cancer patients were treated with radioiodine across a 40-year period; mean follow-up 6.4 ± 6.9 years (median 4.2 years). 656 (39.6%) patients had metastasis or recurrence over the duration of their follow-up. Male gender (odds ratio (OR) 1.38; p = 0.006), Malay race (OR 1.71; p < 0.0001), and age at diagnosis of > 46 years (OR 1.31; p = 0.007) were significantly associated with metastasis or recurrence. Conclusion: Male gender, Malay race, and age at diagnosis of > 46 years were significant risk factors for metastasis or recurrence in Singaporean thyroid cancer patients treated with radioiodine.

Journal Section:
Original Article
Keywords:
Thyroid cancer, Radioiodine, Iodine-131, Metastasis, Recurrence
1.
Schneider DF, Chen H: New developments in the diagnosis and treatment of thyroid cancer. CA Cancer J Clin 2013;63:373-394.
[PubMed]
https://doi.org/10.3322/caac.21195
2.
Sundram F, Robinson BG, Kung A, Lim-Abrahan MA, Bay NQ, Chuan LK, et al.: Well-differentiated epithelial thyroid cancer management in the Asia Pacific region: a report and clinical practice guideline. Thyroid 2006;16:461-469.
[PubMed]
https://doi.org/10.1089/thy.2006.16.461
3.
Cooper DS, Doherty GM, Haugen BR, Kloos RT, Lee SL, Mandel SJ, et al.: American Thyroid Association (ATA) Guidelines Taskforce on Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid 2009;19:1167-1214.
[PubMed]
https://doi.org/10.1089/thy.2009.0110
4.
Singapore Cancer Registry: Interim Annual Registry Report Trends in Cancer Incidence in Singapore 2007-2011. Singapore, National Registry of Diseases Office Singapore, 2011.
5.
Singapore Cancer Registry: Trends in Cancer Incidence in Singapore 1968-2007. Singapore, National Registry of Diseases Office Singapore, 2010, Report No. 7.
6.
Singapore Cancer Registry: Cancer Survival in Singapore 1968-2007. Singapore, National Registry of Diseases Office Singapore, 2011.
7.
Sethi VK: Differentiated thyroid carcinoma - long term survival at the Singapore General Hospital. Ann Acad Med Singapore 1986;15:603-605.
[PubMed]
8.
Sethi VK: Differentiated thyroid cancer: outcome of treatment in 80 cases. Ann Acad Med Singapore 1990;19:435-438.
[PubMed]
9.
Chia KS, Seow A, Lee HP, Shanmugaratnam K: Trends in Cancer Incidence in Singapore 1993-1997. Singapore, Singapore Cancer Registry, 2000, Report No. 5.
10.
Seow A, Koh WP, Chia KS, Shi LM, Lee HP, Shanmugaratnam K: Trends in Cancer Incidence in Singapore 1968-2002. Singapore, Singapore Cancer Registry, 2004, Report No. 6.
11.
Yipintsoi T, Premprabha T, Geater A, Thientunyakij T, Thongmak S: Mortality-related factors in 1056 radioiodine-treated patients with well-differentiated thyroid cancer in southern Thailand. World J Surg 2010;34:230-236.
[PubMed]
https://doi.org/10.1007/s00268-009-0317-7
12.
Htwe TT: Thyroid malignancy among goitrous thyroid lesions: a review of hospital-based studies in Malaysia and Myanmar. Singapore Med J 2012;53:159-163.
[PubMed]
13.
Ibrahim NI, Dahlui M, Aina EN, Al-Sadat N: Who are the breast cancer survivors in Malaysia? Asian Pac J Cancer Prev 2012;13:2213-2218.
[PubMed]
https://doi.org/10.7314/apjcp.2012.13.5.2213
14.
Tuttle RM, Tala H, Shah J, Leboeuf R, Ghossein R, Gonen M, et al.: Estimating risk of recurrence in differentiated thyroid cancer after total thyroidectomy and radioactive iodine remnant ablation: using response to therapy variables to modify the initial risk estimates predicted by the new American Thyroid Association staging system. Thyroid 2010;20:1341-1349.
[PubMed]
https://doi.org/10.1089/thy.2010.0178
© 2015 S. Karger GmbH, Freiburg
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
2015
You do not currently have access to this content.